[ { "Asset": "Zolbetuximab / VYLOY", "Company / rights context": "Astellas", "Modality": "Antibody", "Map stage": "Approved", "Reviewed status": "FDA approved; first-line HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer with chemotherapy", "Competitive relevance / caveat": "Commercial reference; Phase 3 program adding pembrolizumab.", "Gosset drug_id": "67f6aa6a3623f1d2313f6347", "Gosset name": "zolbetuximab", "Gosset phase": "Approved", "Gosset maintenance status": "Approved", "Trial identifiers": "NCT03504397; NCT03653507; NCT06901531", "Registry status by trial": "NCT03504397: ACTIVE_NOT_RECRUITING; NCT03653507: ACTIVE_NOT_RECRUITING; NCT06901531: RECRUITING", "Primary evidence": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma", "Trial URLs": "https://clinicaltrials.gov/study/NCT03504397; https://clinicaltrials.gov/study/NCT03653507; https://clinicaltrials.gov/study/NCT06901531" }, { "Asset": "Satri-cel / CT041", "Company / rights context": "CARsgen", "Modality": "Cell therapy", "Map stage": "Approved", "Reviewed status": "China approved 22 Jun 2026; HER2-negative, CLDN18.2-positive advanced gastric/GEJ cancer after at least two prior lines", "Competitive relevance / caveat": "Regional approval overrides raw Phase 2 classification; pancreatic adjuvant expansion remains investigational.", "Gosset drug_id": "68cc48c7d1b9e2725213eaa7", "Gosset name": "satricabtagene autoleucel", "Gosset phase": "2", "Gosset maintenance status": "Active", "Trial identifiers": "NCT04581473; NCT05911217", "Registry status by trial": "NCT04581473: ACTIVE_NOT_RECRUITING; NCT05911217: RECRUITING", "Primary evidence": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0622/2026062200474.pdf", "Trial URLs": "https://clinicaltrials.gov/study/NCT04581473; https://clinicaltrials.gov/study/NCT05911217" }, { "Asset": "IBI343 / TAK-921 (arcotatug tavatecan)", "Company / rights context": "Innovent; Takeda outside Greater China", "Modality": "ADC", "Map stage": "Filing / readout", "Reviewed status": "China NDA accepted; positive Phase 3 interim analysis announced 4 Jun 2026", "Competitive relevance / caveat": "TOP1-payload ADC; later-line gastric filing and Phase 3 pancreatic expansion. Full comparative data remain important.", "Gosset drug_id": "6833c83f67141c9b36be4c51", "Gosset name": "arcotatug tavatecan", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT06238843; NCT07066098", "Registry status by trial": "NCT06238843: ACTIVE_NOT_RECRUITING; NCT07066098: RECRUITING", "Primary evidence": "https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=601; https://www.takeda.com/newsroom/newsreleases/2025/innovent/", "Trial URLs": "https://clinicaltrials.gov/study/NCT06238843; https://clinicaltrials.gov/study/NCT07066098" }, { "Asset": "LM-302 (tecotabart vedotin; TPX-4589)", "Company / rights context": "LaNova / Sino Biopharmaceutical", "Modality": "ADC", "Map stage": "Filing / readout", "Reviewed status": "China NDA accepted; positive pivotal interim analysis announced 23 Jun 2026", "Competitive relevance / caveat": "MMAE ADC; both pivotal endpoints reported met; detailed results planned early 2027. Current sponsor replaces historical BMS attribution.", "Gosset drug_id": "68cd525180f6166b24a8eece", "Gosset name": "tpx-4589", "Gosset phase": "3", "Gosset maintenance status": "Active", "Trial identifiers": "NCT06351020; NCT07385703", "Registry status by trial": "NCT06351020: ACTIVE_NOT_RECRUITING; NCT07385703: RECRUITING", "Primary evidence": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0623/2026062300456.pdf", "Trial URLs": "https://clinicaltrials.gov/study/NCT06351020; https://clinicaltrials.gov/study/NCT07385703" }, { "Asset": "Sonesitatug vedotin / AZD0901 / CMG901", "Company / rights context": "AstraZeneca", "Modality": "ADC", "Map stage": "Filing / readout", "Reviewed status": "Phase 3 positive OS topline; no approval established in reviewed sources", "Competitive relevance / caveat": "MMAE ADC; 3L+ OS primary and 2L+ OS secondary endpoints met; 2L+ PFS primary not significant. First-line Phase 3 also recruiting.", "Gosset drug_id": "68cbf5a53b71859dcd59d7c9", "Gosset name": "sonesitatug vedotin", "Gosset phase": "3", "Gosset maintenance status": "Active", "Trial identifiers": "NCT06346392; NCT07431281", "Registry status by trial": "NCT06346392: ACTIVE_NOT_RECRUITING; NCT07431281: RECRUITING", "Primary evidence": "https://www.astrazeneca.com/media-centre/press-releases/2026/sone-ve-improved-survival-in-gastric-cancers.html", "Trial URLs": "https://clinicaltrials.gov/study/NCT06346392; https://clinicaltrials.gov/study/NCT07431281" }, { "Asset": "SHR-A1904 (garetatug rezetecan)", "Company / rights context": "Hengrui", "Modality": "ADC", "Map stage": "Phase 3 underway", "Reviewed status": "Phase 3 recruiting", "Competitive relevance / caveat": "TOP1 ADC; second-line gastric/GEJ trial versus chemotherapy; China sites in registry.", "Gosset drug_id": "693f5636d91942c1924b6507", "Gosset name": "garetatug rezetecan", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT06649292", "Registry status by trial": "NCT06649292: RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT06649292" }, { "Asset": "JS107", "Company / rights context": "Junshi", "Modality": "ADC", "Map stage": "Phase 3 underway", "Reviewed status": "Two Phase 3 trials recruiting", "Competitive relevance / caveat": "MMAE ADC; later-line monotherapy and first-line toripalimab/chemotherapy regimens.", "Gosset drug_id": "682e5859a83c5cea4839612d", "Gosset name": "JS107", "Gosset phase": "3", "Gosset maintenance status": "Active", "Trial identifiers": "NCT07284134; NCT07584135", "Registry status by trial": "NCT07284134: RECRUITING; NCT07584135: RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT07284134; https://clinicaltrials.gov/study/NCT07584135" }, { "Asset": "BL-M05D1", "Company / rights context": "Sichuan Baili / SystImmune", "Modality": "ADC", "Map stage": "Phase 3 underway", "Reviewed status": "Phase 3 recruiting", "Competitive relevance / caveat": "Later-line gastric/GEJ ADC program; registry sponsor Sichuan Baili, Gosset lead SystImmune.", "Gosset drug_id": "67f7f9ed9060f7552a055202", "Gosset name": "BL-M05D1", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07518147", "Registry status by trial": "NCT07518147: RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT07518147" }, { "Asset": "ASKB589", "Company / rights context": "AskGene", "Modality": "Antibody", "Map stage": "Phase 3 underway", "Reviewed status": "Phase 3 active, not recruiting", "Competitive relevance / caveat": "First-line CAPOX plus PD-1 inhibitor combination; estimated primary completion Dec 2026.", "Gosset drug_id": "67f804f94afab6023b2a958a", "Gosset name": "ASKB589", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT06206733", "Registry status by trial": "NCT06206733: ACTIVE_NOT_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT06206733" }, { "Asset": "FG-M108 / M108", "Company / rights context": "FutureGen (registry sponsor)", "Modality": "Antibody", "Map stage": "Phase 3 underway", "Reviewed status": "Gastric Phase 3 recruiting; pancreatic Phase 3 not yet recruiting", "Competitive relevance / caveat": "Gastric trial selects HER2-negative, PD-L1 CPS<5 disease and compares M108 plus CAPOX with placebo plus CAPOX. Gastric registry last updated Feb 2024.", "Gosset drug_id": "67f9266da8a467cb7b3fcc63", "Gosset name": "M108", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT06177041; NCT07383922", "Registry status by trial": "NCT06177041: RECRUITING; NCT07383922: NOT_YET_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT06177041; https://clinicaltrials.gov/study/NCT07383922" }, { "Asset": "ASP2138", "Company / rights context": "Astellas", "Modality": "Bispecific", "Map stage": "Phase 3 underway", "Reviewed status": "Phase 3 recruiting; first patient dosed Aug 2026", "Competitive relevance / caveat": "CLDN18.2 x CD3; subcutaneous administration; first-line pembrolizumab/chemotherapy combination.", "Gosset drug_id": "67f90166f079deded49212ad", "Gosset name": "ASP2138", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07673887", "Registry status by trial": "NCT07673887: RECRUITING", "Primary evidence": "https://newsroom.astellas.com/2026-08-25-astellas-doses-first-patient-in-phase-3-study-of-asp2138-in-cldn18-2-postive-and-her2-negative-locally-advanced-unresectable-or-metastatic-gastric-or-gastroesophageal-junction-gej-adenocarcinoma", "Trial URLs": "https://clinicaltrials.gov/study/NCT07673887" }, { "Asset": "QLS31905", "Company / rights context": "Qilu", "Modality": "Bispecific", "Map stage": "Phase 3 underway", "Reviewed status": "Pancreatic Phase 3 recruiting; gastric Phase 3 not yet recruiting", "Competitive relevance / caveat": "CLDN18.2 x CD3; two first-line indication strategies. Do not label the gastric Phase 3 as recruiting.", "Gosset drug_id": "67f7ea269060f7552a054a0a", "Gosset name": "QLS-31905", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07079228; NCT07716449", "Registry status by trial": "NCT07079228: RECRUITING; NCT07716449: NOT_YET_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT07079228; https://clinicaltrials.gov/study/NCT07716449" }, { "Asset": "Osemitamab / TST001", "Company / rights context": "Transcenta", "Modality": "Antibody", "Map stage": "Earlier / pending", "Reviewed status": "Phase 3 registered, not yet recruiting; clinical evidence from earlier phases", "Competitive relevance / caveat": "Enhanced-effector antibody; planned first-line pembrolizumab/chemotherapy study. Registration is not evidence that Phase 3 dosing began.", "Gosset drug_id": "68cc48d0d1b9e2725213eaaa", "Gosset name": "osemitamab", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT06093425", "Registry status by trial": "NCT06093425: NOT_YET_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT06093425" }, { "Asset": "ATG-022", "Company / rights context": "Antengene", "Modality": "ADC", "Map stage": "Earlier / pending", "Reviewed status": "Phase 3 registered, not yet recruiting", "Competitive relevance / caveat": "MMAE ADC; Phase 3 listing updated 31 Aug 2026. Clinical Phase 1/2 program exists.", "Gosset drug_id": "67f820d94afab6023b2ab30a", "Gosset name": "ATG-022", "Gosset phase": "3", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07795346", "Registry status by trial": "NCT07795346: NOT_YET_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT07795346" }, { "Asset": "Givastomig / ABL111", "Company / rights context": "NovaBridge / ABL Bio", "Modality": "Bispecific", "Map stage": "Earlier / pending", "Reviewed status": "Randomized Phase 2 recruiting; Phase 3 planned, not established as started", "Competitive relevance / caveat": "CLDN18.2 x 4-1BB; first-line immunochemotherapy; low-expression eligibility. Sponsor aims for Phase 3 as early as year-end 2026.", "Gosset drug_id": "67f9251aa8a467cb7b3fcb15", "Gosset name": "givastomig", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07432295; NCT04900818", "Registry status by trial": "NCT07432295: RECRUITING; NCT04900818: RECRUITING", "Primary evidence": "https://www.novabridge.com/news-releases/news-release-details/novabridge-reports-first-half-2026-financial-results-and", "Trial URLs": "https://clinicaltrials.gov/study/NCT07432295; https://clinicaltrials.gov/study/NCT04900818" }, { "Asset": "ASP546C / XNW27011", "Company / rights context": "Astellas / Evopoint", "Modality": "ADC", "Map stage": "Earlier / pending", "Reviewed status": "Phase 1/2 recruiting", "Competitive relevance / caveat": "TOP1 ADC; ex-Greater-China rights licensed to Astellas.", "Gosset drug_id": "69c34068774377403427d952", "Gosset name": "ASP546C", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT07488676; NCT06792435", "Registry status by trial": "NCT07488676: RECRUITING; NCT06792435: ACTIVE_NOT_RECRUITING", "Primary evidence": "https://www.astellas.com/system/files/news/2025-05/ee939af947/20250530_en_1.pdf", "Trial URLs": "https://clinicaltrials.gov/study/NCT07488676; https://clinicaltrials.gov/study/NCT06792435" }, { "Asset": "RC118", "Company / rights context": "RemeGen", "Modality": "ADC", "Map stage": "Earlier / pending", "Reviewed status": "Phase 1/2 recruiting in registry; updates dated Jan 2025", "Competitive relevance / caveat": "MMAE ADC; earlier clinical watchlist, with aged registry timelines.", "Gosset drug_id": "67f8159f4afab6023b2aa681", "Gosset name": "RC118", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT05205850; NCT06038396", "Registry status by trial": "NCT05205850: RECRUITING; NCT06038396: RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT05205850; https://clinicaltrials.gov/study/NCT06038396" }, { "Asset": "SKB315 / MK-1200 (Gosset: lucansatuzumab)", "Company / rights context": "Kelun; historical Merck trial sponsor", "Modality": "ADC", "Map stage": "Earlier / pending", "Reviewed status": "Kelun Phase 1 recruiting; Phase 2 registered, not yet recruiting; Merck Phase 1/2 completed", "Competitive relevance / caveat": "TOP1 ADC. Ownership/rights not inferred from a completed Merck trial; distinct regional trial statuses retained.", "Gosset drug_id": "69e773a484eb800a45182476", "Gosset name": "lucansatuzumab", "Gosset phase": "2", "Gosset maintenance status": "Active", "Trial identifiers": "NCT05367635; NCT06242691; NCT07609667", "Registry status by trial": "NCT05367635: RECRUITING; NCT06242691: COMPLETED; NCT07609667: NOT_YET_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT05367635; https://clinicaltrials.gov/study/NCT06242691; https://clinicaltrials.gov/study/NCT07609667" }, { "Asset": "Spevatamig / PT886", "Company / rights context": "Phanes", "Modality": "Bispecific", "Map stage": "Earlier / pending", "Reviewed status": "Phase 1/2 recruiting", "Competitive relevance / caveat": "CLDN18.2 x CD47; differentiates through macrophage checkpoint biology.", "Gosset drug_id": "680390dde845f2ae11fe14d6", "Gosset name": "spevatamig", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT05482893", "Registry status by trial": "NCT05482893: RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT05482893" }, { "Asset": "TAC01-CLDN18.2", "Company / rights context": "Triumvira", "Modality": "Cell therapy", "Map stage": "Earlier / pending", "Reviewed status": "Phase 1/2 active, not recruiting; last update Feb 2025", "Competitive relevance / caveat": "T-cell antigen coupler (TAC) product. Kept distinct from conventional CAR-T despite broad Gosset classification.", "Gosset drug_id": "67f814374afab6023b2aa4d4", "Gosset name": "TAC01-CLDN18.2", "Gosset phase": "2", "Gosset maintenance status": "Stale", "Trial identifiers": "NCT05862324", "Registry status by trial": "NCT05862324: ACTIVE_NOT_RECRUITING", "Primary evidence": "", "Trial URLs": "https://clinicaltrials.gov/study/NCT05862324" }, { "Asset": "SOT102", "Company / rights context": "SOTIO", "Modality": "ADC", "Map stage": "Discontinued", "Reviewed status": "Clinical development discontinued; trial terminated", "Competitive relevance / caveat": "Overrides Gosset Active label; sponsor-authored paper reports unexpected toxicities and discontinued development.", "Gosset drug_id": "67f907faf079deded4921972", "Gosset name": "SOT102", "Gosset phase": "2", "Gosset maintenance status": "Active", "Trial identifiers": "NCT05525286", "Registry status by trial": "NCT05525286: TERMINATED", "Primary evidence": "https://link.springer.com/article/10.1186/s12885-026-16185-x", "Trial URLs": "https://clinicaltrials.gov/study/NCT05525286" }, { "Asset": "EO-3021 / SYSA1801", "Company / rights context": "Elevation / CSPC (territory-specific history)", "Modality": "ADC", "Map stage": "Discontinued", "Reviewed status": "Elevation program discontinued; global territory status not established", "Competitive relevance / caveat": "Elevation discontinuation must not automatically be generalized to all CSPC territories. Chinese Phase 1 registry remains Unknown and old.", "Gosset drug_id": "67f91cb8a8a467cb7b3fc377", "Gosset name": "SYSA1801", "Gosset phase": "Discontinued", "Gosset maintenance status": "Discontinued", "Trial identifiers": "NCT05980416; NCT05009966", "Registry status by trial": "NCT05980416: TERMINATED; NCT05009966: UNKNOWN", "Primary evidence": "https://www.prnewswire.com/news-releases/elevation-oncology-to-discontinue-development-of-eo-3021-advancing-eo-1022-while-evaluating-strategic-options-302406229.html", "Trial URLs": "https://clinicaltrials.gov/study/NCT05980416; https://clinicaltrials.gov/study/NCT05009966" } ]